The study reveals a higher-than-previously-reported number of patients experienced a rebound after Paxlovid treatment, challenging previous assumptions. Despite receiving Paxlovid, individuals with long COVID exhibited similar symptoms to those who didn’t receive the treatment. However, the authors conceded that the study had to rely on patient self-reporting of symptoms and treatment. Despite another year tucked safely into the history books, long COVID continues to live up to its name. The latest news comes from University of California San Francisco researchers who just published the results of a study that shows that Paxlovid failed to cut the risk of developing long covid “for vaccinated, non-hospitalized individuals during their first COVID-19 infection.” Worse still, the researchers discovered that a higher number of patients suffered a rebound than previously reported. The Journal of Medical Virology published the findings in its Jan. 4 issue. https://www.psychiatrist.com/news/study-reveals-paxlovid-does-little-to-stave-off-long-covid/
One of fatigue, shortness of breath, confusion, headache, altered taste and smell, joint pain, muscle aches, cough, chest pain, scratchy throat, nausea, vomiting, diarrhea, fever, chills, red or painful eyes, sore throat, and other at 5.4 months after infection is probably not a very helpful definition of LC.
